Newleos Therapeutics
PrivateLast Round
Series A
Feb 13, 2025
Total Funding Raised
$93.5M
Company Overview
Newleos Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in February 2025.
Newleos Therapeutics is a clinical-stage biotechnology company that develops oral small-molecule therapies for neuropsychiatric disorders including anxiety and substance use disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Newleos Therapeutics Comparables
Compare Newleos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Engrail Therapeutics | 88% | |
| Delix Therapeutics | 81% | |
| Damona Pharmaceuticals | 80% |
For institutional investors. Book with your work email.
Newleos Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Newleos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DCVC Bio | Series A |
| Novo Holdings | Series A |
| Arkin Bio Capital | Series A |
| Goldman Sachs Alternatives | Series A |
| Longwood Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2026
Grew 16% QoQ, from 25 to 29 employees.
- Oct 21, 2025
Timothy Noyes named new President and Chief Executive Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 3, 2026
Newleos Therapeutics, Inc. receives a five-year, milestone-based NIDA grant of up to $15.5M on Nov 3rd '26 to support Phase 1 drug-drug interaction and subsequent Phase 2 efficacy studies of NTX-2001 in cocaine use disorder.
For institutional investors. Book with your work email.
Newleos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Newleos Therapeutics's valuation, stock price, and market status.
Is Newleos Therapeutics a public or private company?
Newleos Therapeutics is a private company.
What is the current stock price of Newleos Therapeutics?
Newleos Therapeutics is a private company, so its shares have no public market price. Caplight tracks Newleos Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Newleos Therapeutics worth (valuation)?
Valuation information for Newleos Therapeutics is not publicly available.
Can I buy Newleos Therapeutics stock?
Newleos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Newleos Therapeutics's last funding round?
Newleos Therapeutics's most recent funding round was Series A on February 13, 2025.
Who are the main investors in Newleos Therapeutics?
Key investors in Newleos Therapeutics include Goldman Sachs Alternatives.
Will Newleos Therapeutics IPO soon?
No public IPO plans have been announced for Newleos Therapeutics.
How can I track Newleos Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Newleos Therapeutics's shares on secondary markets.